

# What You As a Cardiologist Need to Know to Use These Drugs Safely and Effectively in Your Practice

**Dr Jennifer Green MD**

Professor of Medicine

Duke University



AMERICAN  
COLLEGE of  
CARDIOLOGY

# Outline

- Key principles if adding a GLP-1RA
- Key principles if adding an SGLT-2i
- Engagement of other key personnel
  - pharmacy, nursing, CDE, diabetologist



# Adding a GLP-1RA

Generic	Trade Name	CV Outcomes Trial	Results Available
lixisenatide	Adlyxin	ELIXA	2015
<b>liraglutide</b>	<b>Victoza</b>	<b>LEADER</b>	<b>2016</b>
<b>semaglutide</b>	<b>Ozempic</b>	<b>SUSTAIN-6</b>	<b>2016</b>
exenatide	Bydureon	EXSCEL	2017
<b>dulaglutide</b>	<b>Trulicity</b>	<b>REWIND</b>	<b>2019</b>



# Adding a GLP-1RA

- Adjustments to other medications:
  - Cease DPP4 inhibitor: no synergistic benefit, expensive.
  - If HbA1c is:
    - ‘controlled’ (i.e. <7%), consider:
      - Decrease SU by 50%
      - Reduce basal insulin by 20%
    - not ‘controlled’ (i.e. >7%), no need to adjust SU/insulin

Start GLP-1 RA and engage diabetes care provider to assess glycemic response, make additional medication adjustments.

**GLP-1 RA doses generally require up-titration for effectiveness**



# Adding a GLP-1RA (2)

- Anticipate nausea and vomiting:
  - Related to GLP-1 activity → slow gastric motility → satiety
  - Eat slowly, avoid large meals
  - Start at lowest dose
    - Up-titrate if needed for additional glycemic control
    - Start low, go slow! Most settle on a stable dose at 2 weeks.
- Administration education
  - Consider:
    - training up practice nursing staff to assist
    - Referral to local pharmacist for education
    - Referral back to diabetes care provider if not feasible



# Adding an SGLT-2i

Generic	Trade Name	CV Outcomes Trial	Results Available
empagliflozin	Jardiance	EMPA-REG	2015
canagliflozin	Invokana	CANVAS	2017
dapagliflozin	Farxiga	DECLARE	2018
<i>ertugliflozin</i>	<i>Steglatro</i>	<i>VERTIS</i>	Q2 2020



# Adding an SGLT-2i

- Adjustments to other medications:
  - Volume status and blood pressure?
    - Dry or borderline hypotensive: halve diuretic, reduce anti-HTN
    - Euvolemic and/or normotensive: anticipatory guidance
  - If HbA1c is:
    - ‘controlled’ (i.e. <7%), consider:
      - Decrease SU by 50%
      - Reduce basal insulin by 20%
    - not ‘controlled (i.e. >7%), no need to adjust SU/insulin



# Safety considerations

- Key safety considerations:
  - Amputation:
    - Observed in CANVAS, not in CREDENCE or other CVOTs
    - Avoid commencement in ‘active’ foot infection
  - Fournier’s gangrene
    - Rare, but FDA label.
    - Avoid in high risk severe GU infection (chronic incontinence, unable to perform perineal hygiene)
  - eGFR:
    - Not a safety issue, but one of efficacy...





# Dosing with kidney dysfunction

Generic	Trade Name
empagliflozin	Contraindicated eGFR <45 ml/min/1.73m <sup>2</sup>
canagliflozin	<i>Expanded indication – see next slide</i>
dapagliflozin	Not recommended for eGFR <45 ml/min/1.73m <sup>2</sup> ; contraindicated if eGFR <30 ml/min/1.73m <sup>2</sup>
<i>ertugliflozin</i>	Initiation not recommended for eGFR <60ml/min/1.73m <sup>2</sup>



# Dosing with kidney dysfunction

**Table 1: Recommended Dosage**

<b>estimated glomerular filtration rate eGFR (mL/min/1.73 m<sup>2</sup>)</b>	<b>Recommended Dosage</b>
eGFR ≥ 60	100 mg orally once daily, taken before the first meal of the day. Dose can be increased to 300 mg once daily for additional glycemic control.
eGFR 45 to < 60	100 mg once daily.
eGFR 30 to < 45*	
On dialysis	Contraindicated [ <i>see Contraindications</i> ].

\* with albuminuria >300 mg/day.



# Safety considerations

## Euglycemic DKA...

- Uncommon
- Atypical presentation
  - “euglycemic DKA” – less than expected hyperglycemia
  - Reduced/absent ketonuria
  - May delay diagnosis
- If clinical suspicion for DKA
  - i.e. N/V, malaise, abdominal pain, confusion, etc.
  - Check anion gap, serum ketones ( $\beta$ OHB), arterial pH
  - Stop the SGLT2-i



# Tips to avoid DKA

Predisposing factor	Management
Acute illness, diarrhea, MI	Withhold at onset, restart when well and tolerating PO
Major surgery	Withhold at least 3 days prior Restart when euvolemic and tolerating PO.
Volume depleted states (i.e. colonoscopy preparation)	Withhold
Excessive alcohol intake	Stop immediately, restart when tolerating PO intake



# Know your limits

## When to engage a diabetologist?

- Very complex existing regimen:
  - Combination insulin regimen (basal-bolus, mixed preparations)
  - $\geq 3$  oral anti-hyperglycemic medications
- History of severe or recurrent hypoglycemia
- Prior DKA
- Active diabetic foot wound
- To follow up glycemic response, drug tolerability and further adjust regimen





AMERICAN  
COLLEGE *of*  
CARDIOLOGY